Sabse acche Pharma & Healthcare funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 18 direct-growth funds, 0–100 Smart Score se rank kiye hue
Neeche ki interactive table English mein hai — numbers aur fund names dono jagah same hain.
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma And Healthcare HDFC | 81 | Strong Buy | 18.9% | — | — | 1.74 | 2.49 | 14.2 | 20.1 | 0.66 | — | 47.4 | 1.15% | ₹2.6k Cr | 2.8y | |
| SBI Healthcare Opportunities SBI | 77 | Buy | 16.6% | 24.3% | 17.5% | 1.27 | 1.93 | 14.9 | 4.9 | 0.82 | — | 53.5 | 1.03% | ₹5.0k Cr | 13.6y | |
| ICICI Pru Pharma Healthcare And Diagnostics PHD ICICI Pru | 67 | Buy | 7.0% | 24.7% | 16.3% | 1.25 | — | 16.9 | 5.4 | 0.92 | — | — | 1.31% | ₹6.6k Cr | 8.0y | |
| UTI Healthcare UTI | 63 | Buy | 11.8% | 25.3% | 15.1% | 1.23 | 1.99 | 16.7 | 5.0 | 0.91 | — | 41.6 | 1.31% | ₹1.3k Cr | 13.6y | |
| Mirae Asset Healthcare Mirae Asset | 63 | Buy | 13.8% | 24.0% | 15.4% | 1.17 | 1.77 | 16.9 | 3.6 | 0.95 | — | 44.4 | 0.62% | ₹3.3k Cr | 8.1y | |
| DSP Healthcare DSP | 61 | Hold | 10.3% | 22.0% | 15.7% | 1.12 | 1.68 | 15.6 | 3.7 | 0.81 | — | 33.0 | 0.65% | ₹3.5k Cr | 7.6y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 61 | Hold | 16.9% | — | — | 1.14 | 1.61 | 14.6 | 15.8 | 0.68 | — | 48.2 | 1.28% | ₹741 Cr | 2.5y | |
| Kotak Healthcare Kotak | 56 | Hold | 18.9% | — | — | 1.06 | 1.50 | 14.6 | 13.5 | 0.68 | — | 47.3 | 1.04% | ₹678 Cr | 2.6y | |
| PGIM India Healthcare PGIM India | 52 | Hold | 17.6% | — | — | 0.41 | 0.55 | 13.4 | 9.1 | 0.66 | — | 51.6 | 0.86% | ₹103 Cr | 1.7y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 51 | Hold | 15.2% | 23.2% | 14.6% | 1.15 | 1.87 | 16.2 | 3.1 | 0.91 | — | 47.4 | 1.01% | ₹950 Cr | 7.0y | |
| Bajaj FInserv Healthcare Bajaj Finserv | 42 | Avoid | 14.5% | — | — | 0.13 | 0.17 | 13.6 | 3.5 | 0.68 | — | 52.0 | 0.92% | ₹354 Cr | 1.6y | |
| Tata India Pharma & Healthcare Tata | 38 | Avoid | 9.1% | 22.0% | 14.8% | 1.05 | 1.65 | 17.2 | 0.6 | 0.97 | — | 42.8 | 0.94% | ₹1.5k Cr | 10.6y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 38 | Avoid | 6.0% | — | — | -0.02 | -0.02 | 11.7 | 3.9 | 0.56 | — | 46.8 | 1.00% | ₹553 Cr | 1.1y | |
| Nippon India Pharma Nippon India | 33 | Avoid | 7.6% | 20.0% | 13.2% | 1.08 | 1.49 | 15.8 | 2.0 | 0.88 | — | 38.7 | 1.02% | ₹9.0k Cr | 13.6y | |
| LIC MF Healthcare LIC | 27 | Avoid | 10.0% | 22.4% | 12.0% | 1.08 | 1.48 | 16.4 | 2.6 | 0.88 | — | 50.1 | 1.53% | ₹93 Cr | 7.4y | |
| Quant Healthcare Quant | 25 | Avoid | 9.8% | 20.8% | — | 0.83 | 1.15 | 17.2 | 8.3 | 0.92 | — | 44.5 | 1.38% | ₹385 Cr | 3.0y | |
| Bandhan Healthcare Bandhan | 25 | Avoid | — | — | — | — | — | — | — | — | — | 41.8 | 1.26% | ₹291 Cr | 0.7y | |
| ITI Pharma And Healthcare ITI | 24 | Avoid | 6.8% | 20.4% | — | 0.95 | 1.37 | 16.8 | 0.3 | 0.92 | — | 45.2 | 0.95% | ₹252 Cr | 4.7y |
Pharma & Healthcare — Jhatpat jawaab
›Abhi sabse accha Pharma & Healthcare mutual fund kaun sa hai?
HDFC Pharma And Healthcare abhi 18 Pharma & Healthcare funds mein #1 hai — FundLens Smart Score 81/100 (Strong Buy). 3 saal ka return —, expense ratio 1.15% (direct plan). Ranking 24 Jul 2026 ke data se bani hai.
›Kis Pharma & Healthcare fund ka risk-adjusted return sabse accha hai?
Sortino ratio ke hisaab se HDFC Pharma And Healthcare category mein sabse aage hai — 2.49 (Sharpe 1.74). Matlab girawat ke har unit risk par sabse zyada return.
›Sabse kam expense ratio wala Pharma & Healthcare fund kaun sa hai?
Mirae Asset Healthcare — saalana 0.62% (direct plan), category mein sabse kam. Kam fees lambe samay mein aapke favour mein compound hoti hai.
›AUM ke hisaab se sabse chhota Pharma & Healthcare fund kaun sa hai?
LIC MF Healthcare — ₹93 Cr, category mein sabse chhota. Chhote funds phurteele ho sakte hain, par size ko akeli khoobi mat maano.
›Pharma & Healthcare fund mein kitne samay ke liye invested rehna chahiye?
Pharma & Healthcare funds ka risk bahut ooncha hota hai, isliye aam taur par 7+ saal ka nazariya samajhdaari hai. Defensive-growth exposure to pharma, hospitals and diagnostics. Yeh research hai, investment advice nahi.
Yahi jawaab chat mein chahiye? FundLens se poochho